Date: 2014-11-20
Type of information: Collaboration agreement
Compound: myChoice HRD companion diagnostic and niraparib
Company: Myriad Genetics (USA - UT) Tesaro (USA - MA)
Therapeutic area: Cancer - Oncology - Diagnostic
Type agreement: collaboration
Action mechanism: Myriad\'s proprietary Homologous Recombination Deficiency (HRD) test detects DNA scars that indicative of a tumor that has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs. High HRD scores reflective of DNA repair deficiencies are prevalent in all breast cancer subtypes and most other major cancers. In previously published data, Myriad showed that the myChoice HRD test predicted drug response to platinum therapy in triple-negative breast cancer patients.
Disease:
Details: * On November 20, 2014, Tesaro and Myriad Genetics announced a collaboration utilizing Myriad\'s myChoice HRD companion diagnostic (CDx) to identify tumor tissue with a deficiency in homologous recombination. Under the terms of the agreement, Tesaro will utilize Myriad\'s test to enrich the target population for potential responders to niraparib. Myriad will provide testing services and pursue necessary regulatory approvals in support of Tesaro\'s development of niraparib.
Financial terms:
Latest news:
